Drug Profile
GM 237354
Alternative Names: GM-237354Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antifungals
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Candidiasis; Coccidioidomycosis; Histoplasmosis; Mycoses; Protozoan infections
Most Recent Events
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 01 Nov 2000 A preclinical study has been added to the Mycoses pharmacokinetics section
- 24 Jul 2000 A preclinical study has been added to the pharmacokinetics section and the Mycoses antimicrobial activity and pharmacodynamics sections